Management of hepatic encephalopathy in the hospital

Mayo Clinic Proceedings

Volumn 89, Issue 2, 2014, Pages 241-253

  Leise, Michael D ^a   Poterucha, John J ^a   Kamath, Patrick S ^a   Kim, W Ray ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BRANCHED CHAIN AMINO ACID; CIPROFLOXACIN; DISACCHARIDE; LACTITOL; LACTULOSE; MALTODEXTRIN; METRONIDAZOLE; NEOMYCIN; NONABSORBABLE DISACCHARIDE; ORNITHINE ASPARTATE; PLACEBO; PROBIOTIC AGENT; RIFAXIMIN; SORBITOL; UNCLASSIFIED DRUG; VANCOMYCIN; ZINC; CHE; GASTROINTESTINAL AGENT; HELIUM; PROTEIN SYNTHESIS INHIBITOR; RIFAMYCIN;

ADD ON THERAPY; ALBUMIN DIALYSIS; ARTIFICIAL EMBOLISM; CLINICAL FEATURE; COPPER DEFICIENCY; DECOMPENSATED LIVER CIRRHOSIS; DEFECATION; DISEASE SEVERITY; DRUG FORMULATION; DRUG RESPONSE; DYSPEPSIA; GASTROINTESTINAL HEMORRHAGE; HEPATIC ENCEPHALOPATHY; HOSPITAL CARE; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; INCIDENCE; INFECTION; INFORMATION RETRIEVAL; INTERNIST; LIVER CIRRHOSIS; MANDATORY REPORTING; MEDICAL SPECIALIST; MEDLINE; NEPHROTOXICITY; NEUROTOXICITY; OFF LABEL DRUG USE; OTOTOXICITY; PORTOSYSTEMIC ANASTOMOSIS; RECURRENT DISEASE; REMISSION; REVIEW; TRAFFIC ACCIDENT; TREATMENT RESPONSE; ABX; ASTRONOMY; BCAA; BRANCHED-CHAIN AMINO ACIDS; COMPUTER ASSISTED TOMOGRAPHY; COVERT HEPATIC ENCEPHALOPATHY; CT; DIAGNOSTIC; DISEASE MANAGEMENT; DRUG COMBINATION; DX; ELECTROENCEPHALOGRAM; FOOD AND DRUG ADMINISTRATION; L-ORNITHINE-L-ASPARTATE; LOLA; MELD; MHE; MINIMAL HEPATIC ENCEPHALOPATHY; MODEL FOR END-STAGE LIVER DISEASE; MVA; NASOGASTRIC; NG; NOMENCLATURE; OHE; OVERT HEPATIC ENCEPHALOPATHY; RANDOMIZED CONTROLLED TRIAL; RCT; SMT; STANDARD MEDICAL TREATMENT;

ABX; ANTIBIOTIC; BCAA; BRANCHED-CHAIN AMINO ACIDS; CHE; COMPUTED TOMOGRAPHY; COVERT HEPATIC ENCEPHALOPATHY; CT; DIAGNOSTIC; DX; EEG; ELECTROENCEPHALOGRAM; FDA; FOOD AND DRUG ADMINISTRATION; HE; HEPATIC ENCEPHALOPATHY; L-ORNITHINE-L-ASPARTATE; LOLA; MARS; MELD; MHE; MINIMAL HEPATIC ENCEPHALOPATHY; MODEL FOR END-STAGE LIVER DISEASE; MOLECULAR ADSORBENT RECIRCULATING SYSTEM; MOTOR VEHICLE ACCIDENT; MVA; NASOGASTRIC; NG; OHE; OVERT HEPATIC ENCEPHALOPATHY; RANDOMIZED CONTROLLED TRIAL; RCT; SMT; STANDARD MEDICAL TREATMENT;

DISEASE MANAGEMENT; DRUG THERAPY, COMBINATION; GASTROINTESTINAL AGENTS; HEPATIC ENCEPHALOPATHY; HUMANS; INPATIENTS; LACTULOSE; METRONIDAZOLE; NEOMYCIN; PROTEIN SYNTHESIS INHIBITORS; RECURRENCE; RIFAMYCINS; TERMINOLOGY AS TOPIC;

EID: 84897576400     PISSN: 00256196     EISSN: 19425546     Source Type: Journal    
DOI: 10.1016/j.mayocp.2013.11.009     Document Type: Review

References (59)

1. Bajaj JS, Cordoba J, Mullen KD, et al. Review article: the design of clinical trials in hepatic encephalopathy: an International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN) consensus statement. Aliment Pharmacol Ther. 2011;33(7):739-747.
2. Ferenci P, Lockwood A, Mullen K, Tarter R, Weissenborn K, Blei AT. Hepatic encephalopathy: definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology. 2002;35(3):716-721.
3. Bustamante J, Rimola A, Ventura PJ, et al. Prognostic significance of hepatic encephalopathy in patients with cirrhosis. J Hepatol. 1999;30(5):890-895.
4. Huang E, Esrailian E, Spiegel BM. The cost-effectiveness and budget impact of competing therapies in hepatic encephalopathy: a decision analysis. Aliment Pharmacol Ther. 2007;26(8):1147-1161.
5. Stewart CA, Malinchoc M, Kim WR, Kamath PS. Hepatic encephalopathy as a predictor of survival in patients with endstage liver disease. Liver Transpl. 2007;13(10):1366-1371.
6. Stepanova M, Mishra A, Venkatesan C, Younossi ZM. In-hospital mortality and economic burden associated with hepatic encephalopathy in the United States from 2005 to 2009. Clin Gastroenterol Hepatol. 2012;10(9):1034-1041.e1.
7. Neff Guy W, Frederick RT. Assessing treatment patterns in patients with overt hepatic encephalopathy. Hepatology. 2012;56(4):945A.
8. Mohammad RA, Regal RE, Alaniz C. Combination therapy for the treatment and prevention of hepatic encephalopathy. Ann Pharmacother. 2012;46(11):1559- 1563.
9. Volk ML, Tocco RS, Bazick J, Rakoski MO, Lok AS. Hospital readmissions among patients with decompensated cirrhosis. Am J Gastroenterol. 2012;107(2):247-252.
10. Blei AT, Cordoba J. Hepatic encephalopathy. Am J Gastroenterol. 2001;96(7):1968-1976.
11. Bodil A-N, Gluud LL, Gluud C. Non-absorbably disaccharides for hepatic encephalopathy: systematic review of randomised trial. BMJ. 2004;328:1046.
12. Atterbury CE, Maddrey WC, Conn HO. Neomycin-sorbitol and lactulose in the treatment of acute portal-systemic encephalopathy: a controlled, double-blind clinical trial. Am J Digest Dis. 1978;23(5):398-406.
13. Strauss E, Tramote R, Silva EP, et al. Double-blind randomized clinical trial comparing neomycin and placebo in the treatment of exogenous hepatic encephalopathy. Hepatogastroenterology. 1992;39(6):542-545.
14. Cheong HC, Jeong TG, Cho YB, et al. Metronidazole-induced encephalopathy in a patient with liver cirrhosis. Korean J Hepatol. 2011;17(2):157-160.
15. Kim KH, Choi JW, Lee JY, et al. Two cases of metronidazoleinduced encephalopathy [in Korean]. Korean J Gastroenterol. 2005;45(3):195-200.
16. Tarao K, Ikeda T, Hayashi K, et al. Successful use of vancomycin hydrochloride in the treatment of lactulose resistant chronic hepatic encephalopathy. Gut. 1990;31(6):702-706.
17. Uhl MD, Riely CA. Metronidazole in treating portosystemic encephalopathy. Ann Intern Med. 1996;124(4):455.
18. Morgan MH, Read AE, Speller DC. Treatment of hepatic encephalopathy with metronidazole. Gut. 1982;23(1):1-7.
19. Lee JH, Yoon JH, Kim BH, et al. Enterococcus: not an innocent bystander in cirrhotic patients with spontaneous bacterial peritonitis. Eur J Clin Microbiol Infect Dis. 2009;28(1):21-26.
20. Bucci L, Palmieri GC. Double-blind, double-dummy comparison between treatment with rifaximin and lactulose in patients with medium to severe degree hepatic encephalopathy. Curr Med Res Opin. 1993;13(2):109-118.
21. Williams R, James OF, Warnes TW, Morgan MY. Evaluation of the efficacy and safety of rifaximin in the treatment of hepatic encephalopathy: a double-blind, randomized, dose-finding multi-centre study. Eur J Gastroenterol Hepatol. 2000;12(2):203-208.
22. Paik YH, Lee KS, Han KH, et al. Comparison of rifaximin and lactulose for the treatment of hepatic encephalopathy: a prospective randomized study. Yonsei Med J. 2005;46(3):399-407.
23. Sharma BC, Sharma P, Lunia MK, Srivastava S, Goyal R, Sarin SK. A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy. Am J Gastroenterol. 2013;108(9):1458-1463.
24. Takuma Y, Nouso K, Makino Y, Hayashi M, Takahashi H. Clinical trial: oral zinc in hepatic encephalopathy. Aliment Pharmacol Ther. 2010;32(9):1080-1090.
25. Marchesini G, Fabbri A, Bianchi G, Brizi M, Zoli M. Zinc supplementation and amino acid-nitrogen metabolism in patients with advanced cirrhosis. Hepatology. 1996;23(5):1084-1092.
26. Festi D, Mazzella G, Orsini M, et al. Rifaximin in the treatment of chronic hepatic en results of a multicenter study of efficacy and safety. Current Therapeutic Research. 1993;54:598-609.
27. Massa P, Vallerino F, Dodero M. Treatment of hepatic enwith rifaximin: Double-blind, double-dummy study versus lactulose. Eur J Clin Res. 1993;4:7-18.
28. Mas A, Rodés J, Sunyer L, et al. Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a ran double-blind, double-dummy, controlled clinical trial. J Hepatol. 2003;38:51-58.
29. Riggio O, Ariosto F, Merli M, et al. Short-term oral zinc supplementation does not improve chronic hepatic encephalopathy: results of a double-blind crossover trial. Dig Dis Sci. 1991;36(9):1204-1208.
30. Bresci G, Parisi G, Banti S. Management of hepatic encephalopathy with oral zinc supplementation: a long-term treatment. Eur J Med. 1993;2(7):414-416.
31. Reding P, Duchateau J, Bataille C. Oral zinc supplementation improves hepatic encephalopathy: results of a randomised controlled trial. Lancet. 1984;2(8401):493-495.
32. Kircheis G, Nilius R, Held C, et al. Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, double-blind study. Hepatology. 1997;25(6):1351-1360.
33. Stauch S, Kircheis G, Adler G, et al. Oral L-ornithine-L-aspartate therapy of chronic hepatic encephalopathy: results of a placebo-controlled double-blind study. J Hepatol. 1998;28(5):856-864.
34. Abid S, Jafri W, Mumtaz K, et al. Efficacy of L-ornithine-L-aspartate as an adjuvant therapy in cirrhotic patients with hepatic encephalopathy. J Coll Physicians Surg Pak. 2011;21(11):666-671.
35. Kawaguchi T, Izumi N, Charlton MR, Sata M. Branched-chain amino acids as pharmacological nutrients in chronic liver disease. Hepatology. 2011;54(3):1063-1070.
36. Muto Y, Sato S, Watanabe A, et al. Effects of oral branched-chain amino acid granules on event-free survival in patients with liver cirrhosis. Clin Gastroenterol Hepatol. 2005;3(7):705-713.
37. Marchesini G, Bianchi G, Merli M, et al. Nutritional supplementation with branched-chain amino acids in advanced cirrhosis: a double-blind, randomized trial. Gastroenterology. 2003;124(7):1792-1801.
38. Plauth M, Egberts EH, Hamster W, et al. Long-term treatment of latent portosystemic encephalopathy with branched-chain amino acids: a double-blind placebo-controlled crossover study. J Hepatol. 1993;17(3):308-314.
39. Les I, Doval E, Garcia-Martinez R, et al. Effects of branchedchain amino acids supplementation in patients with cirrhosis and a previous episode of hepatic encephalopathy: a randomized study. Am J Gastroenterol. 2011;106(6):1081-1088.
40. Cordoba J, Lopez-Hellin J, Planas M, et al. Normal protein diet for episodic hepatic encephalopathy: results of a randomized study. J Hepatol. 2004;41(1):38-43.
41. Plauth M, Cabre E, Campillo B, et al. ESPEN Guidelines on Parenteral Nutrition: hepatology. Clin Nutr. 2009;28(4):436-444.
42. Laleman W, Simon-Talero M, Maleux G, et al. Embolization of large spontaneous portosystemic shunts for refractory hepatic encephalopathy: a multicenter survey on safety and efficacy. Hepatology. 2013;57(6):2448-2457.
43. Singh S, Kamath PS, Andrews JC, Leise MD. Embolization of spontaneous portosystemic shunts for management of severe persistent hepatic encephalopathy [published online June 14, 2013]. Hepatology. http://dx.doi.org/10.1002/hep. 26575.
44. Banares R, Nevens F, Larsen FS, et al. Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute-on-chronic liver failure: the RELIEF trial. Hepatology. 2013;57(3):1153-1162.
45. Hassanein TI, Tofteng F, Brown RS Jr, et al. Randomized controlled study of extracorporeal albumin dialysis for hepatic encephalopathy in advanced cirrhosis. Hepatology. 2007;46(6):1853-1862.
46. Pares A, Deulofeu R, Cisneros L, et al. Albumin dialysis improves hepatic encephalopathy and decreases circulating phenolic aromatic amino acids in patients with alcoholic hepatitis and severe liver failure. Crit Care. 2009;13(1):R8.
47. Ruggero MA, Argento AC, Heavner MS, Topal JE. Molecular Adsorbent Recirculating System (MARS®) removal of piperacillin/tazobactam in a patient with acetaminophen-induced acute liver failure. Transpl Infect Dis. 2013;15(2):214-218.
48. Sharma BC, Sharma P, Agrawal A, Sarin SK. Secondary prophylaxis of hepatic encephalopathy: an open-label randomized controlled trial of lactulose versus placebo. Gastroenterology. 2009;137(3):885-891:891.e1.
49. Agrawal A, Sharma BC, Sharma P, Sarin SK. Secondary prophylaxis of hepatic encephalopathy in cirrhosis: an open-label, randomized controlled trial of lactulose, probiotics, and no therapy. Am J Gastroenterol. 2012;107(7):1043-1050.
50. Bass NM, Mullen KD, Sanyal A, et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med. 2010;362(12):1071-1081.
51. Riggio O, Efrati C, Catalano C, et al. High prevalence of spontaneous portal-systemic shunts in persistent hepatic encephalopathy: a case-control study. Hepatology. 2005;42(5):1158-1165.
52. Bajaj JS, Schubert CM, Heuman DM, et al. Persistence of cognitive impairment after resolution of overt hepatic encephalopathy. Gastroenterology. 2010;138(7):2332-2340.
53. Riggio O, Ridola L, Pasquale C, et al. Evidence of persistent cognitive impairment after resolution of overt hepatic encephalopathy. Clin Gastroenterol Hepatol. 2011;9(2):181-183.
54. Bajaj JS, Saeian K, Schubert CM, et al. Minimal hepatic encephalopathy is associated with motor vehicle crashes: the reality beyond the driving test. Hepatology. 2009;50(4):1175-1183.
55. Kircheis G, Knoche A, Hilger N, et al. Hepatic encephalopathy and fitness to drive. Gastroenterology. 2009;137(5):1706-1715.e1-9.
56. Wein C, Koch H, Popp B, Oehler G, Schauder P. Minimal hepatic encephalopathy impairs fitness to drive. Hepatology. 2004;39(3):739-745.
57. Cohen SM, Kim A, Metropulos M, Ahn J. Legal ramifications for physicians of patients who drive with hepatic encephalopathy. Clin Gastroenterol Hepatol. 2011;9(2):156-160: quiz e117.
58. Prakash RK, Brown TA, Mullen KD. Minimal hepatic encephalopathy and driving: is the genie out of the bottle? Am J Gastroenterol. 2011;106(8):1415-1416.
59. Bajaj JS, Pinkerton SD, Sanyal AJ, Heuman DM. Diagnosis and treatment of minimal hepatic encephalopathy to prevent motor vehicle accidents: a cost-effectiveness analysis. Hepatology. 2012;55(4):1164-1171.